CAS: 1744-22-5; 6-(Trifluoromethoxy)Benzo[d]Thiazol-2-Amine

上下游产品

CAS号461-82-5 对三氟甲氧基苯胺 | CAS号333-20-0 硫氰酸钾 | CAS号3674-54-2 四丁基硫氰酸铵 | CAS号131395-13-6 2-amino-4-nitro... | CAS号131395-12-5 2-amino-5-nitro... | CAS号133840-98-9 2-亚肼基-6-(三氟甲氧基)... | CAS号133840-96-7 2-氯-6-三氟甲氧基苯并噻唑 | CAS号133840-98-9 2-亚肼基-6-(三氟甲氧基)...

在 盐酸,Blood Peptidase体系中,用 1,4-二氧六环 用作溶剂,化学反应 2.0H,反应生成利鲁唑
参考文献:2-氨基苯并噻唑的α-氨基酸酰胺衍生物的分子内重排
标题:2-氨基苯并噻唑的α-氨基酸酰胺衍生物的分子内重排
摘要:我们发现 2-氨基苯并噻唑的 α-氨基酸酰胺衍生物会发生时间依赖性的热重排,其中氨基攻击噻唑环的 2 位碳以形成 5,5-螺环系统.随后硫离开和空气氧化成相应的对称二硫化物.如果存在构象偏差以进一步促进分子内反应,例如衍生自脯氨酸或 4-氨基哌啶-4-羧酸的 2-氨基苯并噻唑酰胺,则此类产品的分离产率非常高 (>70%).这种重排以前没有描述过 2-氨基苯并噻唑的 α-氨基酸酰胺衍生物.然而,最近报道了涉及 2-氨基脲苯并噻唑的相关反应.
Doi:10.1016/j.Tetlet.2014.05.046

专利信息

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-2024082118-A1
优先权日:2021-05-19
标 题:Topical compositions and methods of preparing the same
发明人：ABRAMOVICH SAGI; AVIDOR GAL; LANDA BENZION
权利人:LANDA LABS 2012 LTD
摘要:There is disclosed a composition comprising a water-insoluble thermoplastic compound capable of stimulating collagen synthesis (CSSC), the CSSC having a molecular weight of more than 0.6 kDa and being dispersed in a polar carrier as nano-elements having an average diameter of 200 nm or less and a viscosity of 107 mPa·s or less. The nano-elements of CSSC can be capable of stimulating the synthesis of skin proteins and/or enabling the delivery of active agents upon their application to a surface to be treated therewith. Methods for preparing the compositions and uses thereof are also provided.

专利号:US-8263755-B2
优先权日:2006-11-20
标题:Synthesis of compounds useful as modulators of amyloid-beta production
发明人：FINDEIS MARK A
权利人:FINDEIS MARK A; SATORI PHARMACEUTICALS INC
摘要:As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

专利号:US-8268936-B2
优先权日:2005-01-04
标题:Synthesis of hybrid block copolymers and uses thereof
发明人：BREITENKAMP KURT; SILL KEVIN N
权利人:BREITENKAMP KURT; SILL KEVIN N; INTEZYNE TECHNOLOGIES INC
摘要:The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and methods of preparing the same.

专利号:US-2012196989-A1
优先权日:2005-02-11
标题:Synthesis of homopolymers and block copolymers
发明人：BREITENKAMP KURT; SILL KEVIN N
权利人:BREITENKAMP KURT; SILL KEVIN N; INTEZYNE TECHNOLOGIES INC
摘要:The present invention relates to the field of polymer chemistry and more particularly to homopolymers and block copolymers and methods of preparing the same.

专利号:WO-0054773-A1
优先权日:1999-03-12
标题:Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
发明人：GARVEY DAVID S
权利人:NITROMED INC; GARVEY DAVID S
摘要:The present invention is directed to novel compositions comprising at least one dopamine agonist in combination with at least one nitric oxide donor (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase). The novel compositions may optionally comprise at least one therapeutic agent, such as, a vasoactive agent, an antimetic agent, and mixtures thereof. The dopamine agonist is preferably apomorphine. The present invention is also directed to methods for treating and/or preventing sexual dysfunctions and/or enhancing sexual responses in patients. In other embodiments, the present invention is directed to methods treating or preventing neurodegenerative diseases, mitochondrial diseases, spinal cord injury, central or psychostimulant addiction, senile dementia, circulatory disorders, cardiovascular disorders, hyperprolactinaemia or myopia. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.